07/26/2026
What do the World Cup, the New England Patriots, Rocky, Moneyball, and the Avengers have in common? At , they all became part of the case for in older patients with recurrent .
Praveen Ramakrishnan Geethakumari, MD, MS, MBA, FACP, brought the clinical evidence to life as he argued that:
⚽ CAR T offers a single-infusion strategy with curative potential
🏈 Durable remission is the real “dynasty” metric
🥊 Age alone should not exclude an older patient from consideration
🧠 Fitness and geriatric assessment should guide selection more than chronology
🦸 CAR T and may ultimately work best as complementary strategies, not permanent rivals
For an older patient with relapsed DLBCL, how should efficacy, fitness, toxicity, treatment burden, and the possibility of durable remission shape the choice between CAR T and bispecific therapy?
That is what makes a Great Debate: serious evidence, opposing positions, and faculty willing to make the discussion memorable. Which analogy takes the championship? Tell us below!
